MM

Mahesh Madhusudan Deshmukh

Active Director Director DIN 08920407
DIN 08920407 First appointment Oct 2020 Primary industry Business Services
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Mahesh Madhusudan Deshmukh

Data last updated:

Mahesh Madhusudan Deshmukh is a Director at Glez Man Pharmaceuticals Private Limited (since 2020). The company operates in Business Services.

DIN 08920407
Primary Designation Director
Industry Business Services
First Appointment 15 Oct 2020
Oldest Company Age 6 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director15 Oct 20202020Active

Board colleagues of Mahesh Madhusudan Deshmukh

NameDINCompanyDesignation
Mayuri Suhas Jawalkar08920408Glez Man Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Glez Man Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Mahesh Madhusudan Deshmukh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mahesh Madhusudan Deshmukh

Mahesh Madhusudan Deshmukh currently holds 1 directorship: Glez Man Pharmaceuticals Private Limited (Director, since 15 Oct 2020).

Mahesh Madhusudan Deshmukh was first appointed on 15 Oct 2020 as Director at Glez Man Pharmaceuticals Private Limited.

The current boards of Mahesh Madhusudan Deshmukh's companies include Mayuri Suhas Jawalkar (Glez Man Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available